Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799286) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer' on Jan. 24.

Brief Summary: The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).

Study Start Date: July 31, 2025

Study Type: INTERVENTIONAL

Condition: Small Cell Lung Carcinoma

Intervention: DRUG: BMS-986489

Specified dose on specified days

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Bristol-...